Sofinnova Closes 725M Euro Fund

Life sciences firm Sofinnova Partners closed its second crossover fund at 725 million euros. The fund aims to support European biotech and medtech companies scaling globally.

Xurve View
Insights:

Life sciences investment firm Sofinnova Partners closed a second crossover fund at €725 million ($799 million) on Monday, exceeding its original target to support European biotechs scaling globally. The raise surpasses the firm's previous crossover vehicle and targets approximately 15 companies nearing commercialisation or public listings.

European life sciences firms frequently encounter capital shortages despite producing robust scientific research, according to Sofinnova partner Kinam Hong. Drugmakers across the continent are concurrently urging governments to accelerate clinical trials and boost healthcare spending to prevent the region from losing ground to the United States and China in pharmaceutical innovation.